# Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

> **NCT01909466** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 141 (actual)

## Conditions studied

- Schizophrenia
- Mental Disorder
- Nervous System Diseases

## Interventions

- **DRUG:** Aripiprazole, OPC-14597

## Key facts

- **NCT ID:** NCT01909466
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2015-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01909466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01909466, "Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01909466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*